共 50 条
- [44] Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction [J]. ESC HEART FAILURE, 2023, 10 (04): : 2524 - 2533
- [47] Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction [J]. ESC HEART FAILURE, 2024,